BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 17222883)

  • 1. Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles.
    Culp TD; Spatz CM; Reed CA; Christensen ND
    Virology; 2007 May; 361(2):435-46. PubMed ID: 17222883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.
    Slupetzky K; Gambhira R; Culp TD; Shafti-Keramat S; Schellenbacher C; Christensen ND; Roden RB; Kirnbauer R
    Vaccine; 2007 Mar; 25(11):2001-10. PubMed ID: 17239496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16.
    Varsani A; Williamson AL; de Villiers D; Becker I; Christensen ND; Rybicki EP
    J Virol; 2003 Aug; 77(15):8386-93. PubMed ID: 12857908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity.
    Zhao Q; Modis Y; High K; Towne V; Meng Y; Wang Y; Alexandroff J; Brown M; Carragher B; Potter CS; Abraham D; Wohlpart D; Kosinski M; Washabaugh MW; Sitrin RD
    Virol J; 2012 Feb; 9():52. PubMed ID: 22356831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses.
    Combita AL; Touzé A; Bousarghin L; Christensen ND; Coursaget P
    J Virol; 2002 Jul; 76(13):6480-6. PubMed ID: 12050360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type-specific and cross-reactive antibodies induced by human papillomavirus 31 L1/L2 virus-like particles.
    Xu Y; Wang Q; Han Y; Song G; Xu X
    J Med Microbiol; 2007 Jul; 56(Pt 7):907-913. PubMed ID: 17577054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.
    Jagu S; Karanam B; Gambhira R; Chivukula SV; Chaganti RJ; Lowy DR; Schiller JT; Roden RB
    J Natl Cancer Inst; 2009 Jun; 101(11):782-92. PubMed ID: 19470949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types.
    Christensen ND; Cladel NM; Reed CA; Budgeon LR; Embers ME; Skulsky DM; McClements WL; Ludmerer SW; Jansen KU
    Virology; 2001 Dec; 291(2):324-34. PubMed ID: 11878901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Establishment and application of human papillomavirus type 16 pseudovirions neutralization assay].
    Lu WX; Cheng T; Li SW; Pan HR; Shen WT; Chen YX; Zhang T; Zheng Z; Zhang J; Xia NS
    Sheng Wu Gong Cheng Xue Bao; 2006 Nov; 22(6):990-5. PubMed ID: 17168325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6.
    Christensen ND; Reed CA; Cladel NM; Hall K; Leiserowitz GS
    Virology; 1996 Oct; 224(2):477-86. PubMed ID: 8874508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
    Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
    Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A surface immunodeterminant of human papillomavirus type 16 minor capsid protein L2.
    Kawana K; Matsumoto K; Yoshikawa H; Taketani Y; Kawana T; Yoshiike K; Kanda T
    Virology; 1998 Jun; 245(2):353-9. PubMed ID: 9636375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations on the FG surface loop of human papillomavirus type 16 major capsid protein affect recognition by both type-specific neutralizing antibodies and cross-reactive antibodies.
    Carpentier GS; Fleury MJ; Touzé A; Sadeyen JR; Tourne S; Sizaret PY; Coursaget P
    J Med Virol; 2005 Dec; 77(4):558-65. PubMed ID: 16254978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.
    Godi A; Boampong D; Elegunde B; Panwar K; Fleury M; Li S; Zhao Q; Xia N; Christensen ND; Beddows S
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32967963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
    Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M
    J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibodies recognizing cross-neutralization epitopes in human papillomavirus 16 minor capsid protein L2.
    Nakao S; Mori S; Kondo K; Matsumoto K; Yoshikawa H; Kanda T
    Virology; 2012 Dec; 434(1):110-7. PubMed ID: 23051711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2.
    Seitz H; Schmitt M; Böhmer G; Kopp-Schneider A; Müller M
    Int J Cancer; 2013 Feb; 132(3):E139-48. PubMed ID: 22961598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera.
    Carter JJ; Wipf GC; Madeleine MM; Schwartz SM; Koutsky LA; Galloway DA
    J Virol; 2006 May; 80(10):4664-72. PubMed ID: 16641259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types.
    Rizk RZ; Christensen ND; Michael KM; Müller M; Sehr P; Waterboer T; Pawlita M
    J Gen Virol; 2008 Jan; 89(Pt 1):117-129. PubMed ID: 18089735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies.
    Christensen ND; Dillner J; Eklund C; Carter JJ; Wipf GC; Reed CA; Cladel NM; Galloway DA
    Virology; 1996 Sep; 223(1):174-84. PubMed ID: 8806551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.